News & Press Releases

Integrity Applications to Present GlucoTrack® Data at American Diabetes Association’s 77th Scientific Sessions

May 23rd, 2017

Download

Integrity Applications to Present GlucoTrack® Data at American Diabetes Association’s 77th Scientific Sessions

Wilmington, Delaware, and Ashdod, Israel, May 23, 2017 /PRNewswire/ — Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels of people with type 2 diabetes and prediabetes, today announced that the results of a study evaluating the influence of medications on the accuracy of GlucoTrack® will be presented at the American Diabetes Association’s (ADA) 77th Scientific Sessions, June 9-13, 2017, in San Diego, CA.

The presentation details are as follows:

 

Poster Title:               Influence of Medications on the Accuracy of GlucoTrack® – A Non-invasive Glucose Monitoring Device

Abstract #:                 937

Room:                         Hall B

Date:                           Saturday, June 10, 2017

Time:                          11:30AM – 12:30PM

Presenter:                   Amit Rozner, Senior Research Engineer at Integrity Applications

 

For more information, please visit the company website at www.integrity-app.com.

 

About GlucoTrack®

GlucoTrack® is a truly non-invasive monitoring device that rapidly measures and displays an individual’s glucose level without finger pricking or any pain.

GlucoTrack® features a small sensor that clips to the earlobe and measures the user’s glucose level using innovative and patented sensor technology. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The derived glucose measurements are stored in the device and calculates a projected HbA1c level using a validated algorithm. The device also displays the glucose values graphically allowing the user to monitor glucose over a period of time.

GlucoTrack® has received CE Mark and KFDA approvals for type 2 diabetes and prediabetics, and is currently in the early stages of commercialization in Europe, South Korea and other geographies.

GlucoTrack® is expected to begin clinical trials for United States FDA approval in late 2017. The product is currently experimental in the United States and is limited to investigational use only.

 

About Integrity Applications, Inc.

Integrity Applications was founded in 2001 and is focused on the design, development and commercialization of non-invasive glucose monitoring technologies for patients with diabetes and pre-diabetes. The company has developed GlucoTrack®, a proprietary noninvasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Ashdod, Israel. For more information, please visit www.integrity-app.com and www.glucotrack.com.

 

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “expect”, “plan” and “will” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 30, 2017.

 

MEDIA CONTACTS

Erich Sandoval / Amy Wheeler

Lazar Partners Ltd.

esandoval@lazarpartners.com / awheeler@lazarpartners.com

+1 (917) 497-2867 / +1 (646) 871-8486

 

INVESTOR CONTACTS

Matthew Ventimiglia

Lazar Partners Ltd.

mventimiglia@lazarpartners.com

+1 (212) 599-1265

 

Sami Sassoun, CFO Integrity Applications

SamiS@integrity-app.com

+972 (8) 675-7878 Ext. 400

 

###

Back to all news & press releases

Sign up to our newsletter
To receive occasional news updates

LinkedIn Facebook Twitter